Last reviewed · How we verify
NCT04018846: REVATEC
The Future of Revascularization Using a Bioprotec Graft
trial testing Revascularization using a BIOPROTEC Graft in Peripheral Artery Disease in 46 participants. Completed in 7 October 2022.
7 October 2021
Quick facts
| Lead sponsor | Hôpital NOVO |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 46 |
| Start date | 1 September 2018 |
| Primary completion | 7 October 2021 |
| Estimated completion | 7 October 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Revascularization using a BIOPROTEC Graft
Conditions studied
- Peripheral Artery Disease — all drugs for Peripheral Artery Disease →
Sponsor
Hôpital NOVO — full company profile →
Who can join
18 and older, any sex, with Peripheral Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this study is the rate assessment of rescued limbs, one year after a BIOPROTEC vascular graft.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
History, progress and future challenges of artificial blood vessels: a narrative review.
Hu K, Li Y, Ke Z, Yang H, et al · · 2022 · cited 43× · PMID 35837341 · DOI 10.12336/biomatertransl.2022.01.008
Verify or expand the search:
- PubMed search for NCT04018846
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral Artery Disease
Currently open trials in the same condition.
- NCT07374601 — The Value of Super-resolution Ultrasound Imaging for Peripheral Artery Disease · recruiting
- NCT06686121 — Improving Mobility After Revascularization in Peripheral Artery Disease · Phase 3 · recruiting
- NCT04433572 — Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee · Phase 3 · recruiting
- NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
- NCT07012070 — Improving Walking Performance in Patients With Peripheral Artery Disease Through Wearable Activity Trackers · NA · recruiting
Other Hôpital NOVO trials
Trials by the same sponsor.
- NCT07394478 — Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica · not yet recruiting
- NCT07412340 — Disarticulation Septoplasty Versus Classical Way · not yet recruiting
- NCT07298070 — Functional and Aesthetic Outcomes Following Lower Lip Reconstruction · not yet recruiting
- NCT07257094 — Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Reha · recruiting
- NCT07505706 — Patient Journey in Palliative Care Within the NOVO Hospital Group. · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04018846 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hôpital NOVO
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04018846.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing